Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $92.27 (market cap $5.70B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: State Street SPDR Bloomberg High Yield Bond ETF is far larger — about 5.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg High Yield Bond ETF for 63 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| JNK | MRVI | |
|---|---|---|
Market Cap | $5.70B | $972.90M |
Volume | 1,722,684 | 4,325,710 |
Sector | Fixed Income | Health |
52-Week High | $98.02 | $9.00 |
52-Week Low | $92.25 | $2.83 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK trades at $92.66, down 0.29% amid a bearish technical outlook with selling pressure across moving averages and oscillators. The ETF shows consistent dividend payments of $0.53 but lacks fundamental ratio data. Recent market focus centers on rising bond yields and geopolitical tensions affecting high-yield bond markets.
Outlook remains cautious as technical indicators signal bearish momentum with RSI at overbought levels. Investment opportunities include steady dividend income, while risks involve sensitivity to interest rate hikes and broader bond market volatility. The ETF's performance is closely tied to credit market conditions.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
